[go: up one dir, main page]

AU2001290801A1 - Peptide epitopes recognized by antigen specific cd4+ t lymphocytes - Google Patents

Peptide epitopes recognized by antigen specific cd4+ t lymphocytes

Info

Publication number
AU2001290801A1
AU2001290801A1 AU2001290801A AU9080101A AU2001290801A1 AU 2001290801 A1 AU2001290801 A1 AU 2001290801A1 AU 2001290801 A AU2001290801 A AU 2001290801A AU 9080101 A AU9080101 A AU 9080101A AU 2001290801 A1 AU2001290801 A1 AU 2001290801A1
Authority
AU
Australia
Prior art keywords
lymphocytes
antigen specific
peptide epitopes
epitopes recognized
recognized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290801A
Inventor
Roman Chicz
Andy Tomlinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MGI Pharma Biologics Inc
Original Assignee
Zycos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zycos Inc filed Critical Zycos Inc
Publication of AU2001290801A1 publication Critical patent/AU2001290801A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2001290801A 2000-09-12 2001-09-12 Peptide epitopes recognized by antigen specific cd4+ t lymphocytes Abandoned AU2001290801A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23218500P 2000-09-12 2000-09-12
US60/232,185 2000-09-12
PCT/US2001/028467 WO2002022803A2 (en) 2000-09-12 2001-09-12 Peptide epitopes recognized by antigen specific cd4+ t lymphocytes

Publications (1)

Publication Number Publication Date
AU2001290801A1 true AU2001290801A1 (en) 2002-03-26

Family

ID=22872177

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290801A Abandoned AU2001290801A1 (en) 2000-09-12 2001-09-12 Peptide epitopes recognized by antigen specific cd4+ t lymphocytes

Country Status (3)

Country Link
US (1) US20040071726A1 (en)
AU (1) AU2001290801A1 (en)
WO (1) WO2002022803A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500647A1 (en) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie USE OF A VACCINATE
EP1537423B1 (en) * 2002-09-09 2006-05-31 Medifact-Publishing GmbH Method for the local detection of inflammation and allergy mediators
AU2003295189A1 (en) * 2002-12-17 2004-07-09 Fondazione Centro San Raffaele Del Monte Tabor Carcinoembryonic antigen-specific immunodominant epitope recognized by cd4+t cells and uses thereof
EP1715343B1 (en) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
US20130142878A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
CN107266552B (en) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 Tumor antigen short peptide derived from PRAME

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951917B1 (en) * 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US5726020A (en) * 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
AU3102299A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Compositions and methods for gene-based vaccines to provoke T cell responses
EP1173767B1 (en) * 1999-04-21 2008-04-09 MGI PHARMA Biologics, Inc. Peptide epitopes recognized by disease promoting cd4+ t lymphocytes
ATE444309T1 (en) * 2000-08-08 2009-10-15 Immunomedics Inc IMMUNOTHERAPY FOR CRONIC MYELOCYTIC LEUKEMIA WITH NAKED ANTI-NCA-90 ANTIBODIES

Also Published As

Publication number Publication date
WO2002022803A2 (en) 2002-03-21
US20040071726A1 (en) 2004-04-15
WO2002022803A9 (en) 2004-04-22
WO2002022803A3 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
MXPA03008031A (en) Expression technology for proteins containing a hybrid isotype antibody moiety.
AU2002222112A1 (en) Hybrid antibodies
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
AU1951201A (en) Peptide antigens
AU2002226211A1 (en) Individualized anti-cancer antibodies
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
AU2003262094A1 (en) Cancer antigen peptide preparation
AU2002254511A1 (en) Multiple simultaneous antigen detection by immunohistochemistry
AU2003294220A1 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
AU2001290801A1 (en) Peptide epitopes recognized by antigen specific cd4+ t lymphocytes
AU2001278737A1 (en) Collagen-binding hybrid polypeptide
AU2003283963A1 (en) Mage-c2 antigenic peptides and uses thereof
AU2001291050A1 (en) Viral chemokine-tumur antigen fusion proteins
AU2002237217A1 (en) Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity
AU2002232707A1 (en) Transmembrane proteins
AU2001295582A1 (en) Tumour-related antigens
AU2002220924A1 (en) Antibodies, peptides, analogs and uses thereof
AU2002221132A1 (en) Novel antibody
WO2002026785A3 (en) Epitopes of virus hepatitis c specifically cd4+ t lymphocytes
AU2003225866A1 (en) Peptide epitopes recognized by antigen specific cd8+ t lymphocytes
AU2002365187A1 (en) Epitope synchronization in antigen presenting cells
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU2003271093A1 (en) Antigen recognizing antibody
AU2002224379A1 (en) Clasp-2 transmembrane proteins